Summit Creek Advisors LLC Sells 14,940 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Summit Creek Advisors LLC reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 214,996 shares of the medical instruments supplier’s stock after selling 14,940 shares during the period. LeMaitre Vascular makes up approximately 2.4% of Summit Creek Advisors LLC’s portfolio, making the stock its 13th largest position. Summit Creek Advisors LLC’s holdings in LeMaitre Vascular were worth $17,690,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Jackson Creek Investment Advisors LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $1,158,000. Versor Investments LP bought a new position in shares of LeMaitre Vascular in the second quarter valued at $387,000. nVerses Capital LLC grew its stake in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of LeMaitre Vascular in the second quarter valued at $75,000. Finally, Kings Path Partners LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at $1,694,000. 84.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several analyst reports. Roth Capital raised shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. JMP Securities raised their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Finally, Roth Mkm reaffirmed a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday, May 31st. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average price target of $94.40.

LeMaitre Vascular Stock Performance

LMAT opened at $88.09 on Friday. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $92.90. The stock has a fifty day moving average of $85.47 and a 200-day moving average of $76.08. The company has a market capitalization of $1.98 billion, a P/E ratio of 58.34, a P/E/G ratio of 2.38 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same quarter in the previous year, the business posted $0.37 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at $1,158,335.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,251 shares of company stock worth $3,714,994. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.